In 2023, the number of confirmed RR-/MDR-TB cases in China stood at approximately 22.05 thousand. From 2024 onwards, forecasts indicate a steady increase from 23.08 thousand in 2024 to 27.26 thousand by 2028. Year-on-year growth rates show consistent increases of around 4.5% annually, indicating a persistent upward trend in RR-/MDR-TB cases.
The Compound Annual Growth Rate (CAGR) over the five-year period from 2023 to 2028 is approximately 4.3%. This suggests a continuous, albeit moderate, rise in the number of cases each year, reflecting ongoing challenges in managing drug-resistant tuberculosis.
Future trends to watch include the impact of public health initiatives aimed at improving diagnosis and treatment, potential drug innovations, and efforts to strengthen healthcare infrastructure, all of which could influence the trajectory of RR-/MDR-TB cases in the coming years.
